Search This Blog

Tuesday, January 14, 2020

Nektar Therapeutics tumbles after FDA panel thumbs down

The vote at today’s joint FDA advisory committee meeting was 27 – 0 against approval of Nektar Therapeutics’ (NASDAQ:NKTR) oxycodegol for chronic low back pain.
Shares down 12% after hours.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)